Literature DB >> 12350353

Human immunodeficiency virus type 1 reverse transcription is stimulated by tat from other lentiviruses.

C William Hooker1, Julie Scott, Ann Apolloni, Emma Parry, David Harrich.   

Abstract

The tat gene is required by HIV-1 for efficient reverse transcription and this function of Tat can be distinguished from its role in transcription by RNA polymerase II using tat point mutations that abrogate each function independently. The mechanism of Tat's role in reverse transcription, however, is not known, nor is it known whether this role is conserved among trans-activating factors in other retroviruses. Here we examine the abilities of heterologous viral trans-activating proteins from jembrana disease virus (jTat), HIV-2 (Tat2), and equine infectious anemia virus (eTat) to substitute for HIV-1 Tat (Tat1) and restore reverse transcription in HIV-1 carrying an inactivated tat gene. Natural endogenous reverse transcription assays showed that trans-activators from some retroviruses (Tat2 and jTat, but not eTat) could substitute for Tat1 in complementation of HIV-1 reverse transcription. Finally, we show that Y47 is critical for Tat1 to function in reverse transcription, but not HIV-1 gene expression. We mutated the homologous position in jTat to H62Y and found it did not improve its ability to stimulate reverse transcription, but an H62A mutation did inhibit jTat complementation. These data highlight the finding that the role of Tat in reverse transcription is not related to trans-activation and demonstrate that other tat genes conserve this function.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12350353     DOI: 10.1006/viro.2002.1554

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  8 in total

1.  Construction of a doxycycline-dependent simian immunodeficiency virus reveals a nontranscriptional function of tat in viral replication.

Authors:  Atze T Das; Bep Klaver; Alex Harwig; Monique Vink; Marcel Ooms; Mireille Centlivre; Ben Berkhout
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

2.  In vitro synthesis of long DNA products in reactions with HIV-RT and nucleocapsid protein.

Authors:  Reshma M Anthony; Jeffrey J Destefano
Journal:  J Mol Biol       Date:  2006-10-06       Impact factor: 5.469

3.  A mutant tat protein inhibits HIV-1 reverse transcription by targeting the reverse transcription complex.

Authors:  Min-Hsuan Lin; Ann Apolloni; Vincent Cutillas; Haran Sivakumaran; Sally Martin; Dongsheng Li; Ting Wei; Rui Wang; Hongping Jin; Kirsten Spann; David Harrich
Journal:  J Virol       Date:  2015-02-11       Impact factor: 5.103

4.  Semen Exosomes Promote Transcriptional Silencing of HIV-1 by Disrupting NF-κB/Sp1/Tat Circuitry.

Authors:  Jennifer L Welch; Hussein Kaddour; Patrick M Schlievert; Jack T Stapleton; Chioma M Okeoma
Journal:  J Virol       Date:  2018-10-12       Impact factor: 5.103

5.  Human immunodeficiency virus type 1 protease regulation of tat activity is essential for efficient reverse transcription and replication.

Authors:  Ann Apolloni; C William Hooker; Johnson Mak; David Harrich
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

6.  Dynamic interactions of the HIV-1 Tat with nucleic acids are critical for Tat activity in reverse transcription.

Authors:  Christian Boudier; Nicolas Humbert; Françoise Chaminade; Yingying Chen; Hugues de Rocquigny; Julien Godet; Olivier Mauffret; Philippe Fossé; Yves Mély
Journal:  Nucleic Acids Res       Date:  2013-10-22       Impact factor: 16.971

7.  Functional relevance of nonsynonymous mutations in the HIV-1 tat gene within an epidemiologically-linked transmission cohort.

Authors:  Haran Sivakumaran; Bin Wang; M John Gill; Brenda Beckholdt; Nitin K Saksena; David Harrich
Journal:  Virol J       Date:  2007-10-25       Impact factor: 4.099

Review 8.  Vehicles of intercellular communication: exosomes and HIV-1.

Authors:  Jennifer L Welch; Jack T Stapleton; Chioma M Okeoma
Journal:  J Gen Virol       Date:  2019-01-31       Impact factor: 3.891

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.